ReviewCurrent topics in medicinal chemistry2025
Common Signaling Pathways in Cancer and Alzheimer's Disease May Point to New Treatments.
Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and Alzheimer's disease (AD) are among the most prevalent diseases in contemporary society, exerting profound psychological and physical distress on affected individuals and their kin. There is an emerging consensus from epidemiological studies suggesting a potential inverse relationship between the two conditions; that is, the presence of one disease might offer some level of protection against the other. The etiology of both cancer and AD is intricately linked to dysregulation and perturbations in critical signaling pathways. These pathways, along with the diverse factors they encompass, exert distinct influences on the pathogenesis of two diseases. In this paper, we make a short review of the different mutations in the relevant signaling pathways between cancer and AD and introduce a few representative drugs for the two diseases based on various targets to provide a new idea for treating cancer and AD.
Indexed as
Identifiers
40059419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.